CY1118053T1 - Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea - Google Patents

Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea

Info

Publication number
CY1118053T1
CY1118053T1 CY20161100951T CY161100951T CY1118053T1 CY 1118053 T1 CY1118053 T1 CY 1118053T1 CY 20161100951 T CY20161100951 T CY 20161100951T CY 161100951 T CY161100951 T CY 161100951T CY 1118053 T1 CY1118053 T1 CY 1118053T1
Authority
CY
Cyprus
Prior art keywords
human
resolution
cea
antibody
medicinal compositions
Prior art date
Application number
CY20161100951T
Other languages
English (en)
Inventor
Ralf LUTTERBÜSE
Petra Mayer
Evelyne Schaller
Doris Rau
Susanne Mangold
Peter Kufer
Alexander Murr
Monika Wissinger
Tobias Raum
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Publication of CY1118053T1 publication Critical patent/CY1118053T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με φαρμακευτικές συνθέσεις για την αντιμετώπιση ενός επιθηλιακού όγκου σε έναν άνθρωπο, με την εν λόγω φαρμακευτική σύνθεση να περιλαμβάνει ένα διπλής ειδικότητας μονής αλυσίδας αντίσωμα το οποίο έχει έναν πρώτο τομέα δέσμευσης ο οποίος δεσμεύεται ειδικά με ανθρώπινο CD3, και έναν δεύτερο τομέα δέσμευσης ο οποίος δεσμεύεται ειδικά με ανθρώπινο CEA, όπου ο εν λόγω δεύτερος τομέας δέσμευσης περιλαμβάνει τουλάχιστον ένα μέρος της CDR-H3 ή την πλήρη CDR-H3 του ποντικίσιου μονόκλωνου αντισώματος Α5Β7. Επιπλέον, διαδικασίες για την παραγωγή των εν λόγω φαρμακευτικών συνθέσεων καθώς επίσης ιατρικές/φαρμακευτικές χρήσεις για τα μόρια ειδικού διπλής ειδικότητας μονής αλυσίδας αντισώματος το οποίο φέρει ειδικότητες για το ανθρώπινο CD3 αντιγόνο και το ανθρώπινο CEA αντιγόνο γνωστοποιούνται.
CY20161100951T 2005-12-21 2016-09-23 Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea CY1118053T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75196305P 2005-12-21 2005-12-21
EP05028064 2005-12-21
US78086106P 2006-03-10 2006-03-10
PCT/EP2006/012425 WO2007071426A1 (en) 2005-12-21 2006-12-21 Pharmaceutical compositions with resistance to soluble cea
EP06841112.3A EP1976880B1 (en) 2005-12-21 2006-12-21 Pharmaceutical compositions with resistance to soluble cea

Publications (1)

Publication Number Publication Date
CY1118053T1 true CY1118053T1 (el) 2017-06-28

Family

ID=40413962

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100951T CY1118053T1 (el) 2005-12-21 2016-09-23 Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea

Country Status (25)

Country Link
US (3) US8394926B2 (el)
EP (2) EP1976880B1 (el)
JP (2) JP5399712B2 (el)
KR (1) KR101287777B1 (el)
CN (1) CN101370827B (el)
AU (1) AU2006328886C1 (el)
BR (1) BRPI0620632A2 (el)
CA (1) CA2633766C (el)
CY (1) CY1118053T1 (el)
DK (1) DK1976880T3 (el)
ES (1) ES2595091T3 (el)
HK (1) HK1115890A1 (el)
HR (1) HRP20161216T1 (el)
HU (1) HUE031151T2 (el)
IL (1) IL192277A (el)
LT (1) LT1976880T (el)
ME (1) ME02581B (el)
NZ (1) NZ569204A (el)
PL (1) PL1976880T3 (el)
PT (1) PT1976880T (el)
RS (1) RS55181B1 (el)
RU (2) RU2426743C2 (el)
SG (1) SG193141A1 (el)
WO (1) WO2007071426A1 (el)
ZA (1) ZA200805400B (el)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2412816B1 (en) 2004-07-26 2014-12-03 Pfenex Inc. Process for improved protein expression by strain engineering
US20090226444A1 (en) * 2005-12-21 2009-09-10 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
ZA200805400B (en) 2005-12-21 2009-09-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2142651B1 (en) 2007-04-27 2013-05-22 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
US8287865B2 (en) * 2009-09-16 2012-10-16 Immunomedics, Inc. Class I anti-CEA antibodies and uses thereof
US20130035249A1 (en) * 2009-12-01 2013-02-07 Medimmune, Llc Methods and compositions for detecting and treating cea-expressing cancers
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
WO2013012414A1 (en) * 2011-07-18 2013-01-24 Medimmune, Llc Dosing regimens for treatment of cea-expressing cancers
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013162748A1 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA3169263A1 (en) 2012-11-13 2014-05-22 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
MY171100A (en) 2012-11-20 2019-09-25 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
CN105143270B (zh) 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
KR20210094673A (ko) 2013-02-26 2021-07-29 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
UY35484A (es) 2013-03-15 2014-10-31 Amgen Res Munich Gmbh Molécula de unión de cadena simple que comprenden ABP de extremo N
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
CR20160534A (es) 2014-04-27 2017-04-25 Ccam Biotherapeutics Ltd Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
CN106661119A (zh) 2014-07-01 2017-05-10 辉瑞公司 双特异性异二聚化双抗体及其用途
KR20230109773A (ko) 2015-02-24 2023-07-20 바이오아트라, 인코퍼레이티드 조건부 활성 생체 단백질
CN106432502B (zh) * 2015-08-10 2020-10-27 中山大学 用于治疗cea阳性表达肿瘤的双特异纳米抗体
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CA2990755A1 (en) 2015-10-02 2017-04-06 F. Hoffman-La Roche Ag Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
CA2997406C (en) 2015-12-09 2024-05-28 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
WO2017118675A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
AU2017273147B2 (en) 2016-06-02 2024-06-13 Immunocore Limited Dosing regimen for GP100-specific TCR - anti-CD3 SCFV fusion protein
CN107663240B (zh) 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
CA3039430A1 (en) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
BR112019013189A2 (pt) 2017-01-03 2019-12-10 Hoffmann La Roche moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa
CN107056952A (zh) * 2017-05-10 2017-08-18 常州市第人民医院 Cea.car‑t及其制备与应用
CN107058234B (zh) * 2017-05-12 2019-09-13 常州市第一人民医院 Car.il-33-t及其制备与应用
CN113896797B (zh) 2017-08-01 2023-05-09 Ab工作室有限公司 双特异性抗体及其用途
EP3704155A2 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Combination therapy with targeted ox40 agonists
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
US20210221908A1 (en) 2018-06-03 2021-07-22 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
EP3818082A1 (en) 2018-07-04 2021-05-12 F. Hoffmann-La Roche AG Novel bispecific agonistic 4-1bb antigen binding molecules
CN113286821A (zh) 2018-12-21 2021-08-20 豪夫迈·罗氏有限公司 靶向肿瘤的激动性cd28抗原结合分子
EP3920972A1 (en) 2019-02-07 2021-12-15 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
BR112021025034A2 (pt) 2019-06-13 2022-04-26 Bolt Biotherapeutics Inc Imunoconjugado, composto aminobenzazepina-ligante, composição farmacêutica, métodos para tratar câncer e para preparar um imunoconjugado e uso de um imunoconjugado
WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
CA3148694A1 (en) 2019-09-03 2021-03-11 Romas Kudirka Aminoquinoline compounds, immunoconjugates, and uses thereof
BR112022004995A2 (pt) 2019-09-18 2022-06-21 Lamkap Bio Alpha AG Anticorpos biespecíficos contra ceacam5 e cd3
US20220347310A1 (en) 2019-09-30 2022-11-03 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
IL292396A (en) 2019-10-25 2022-06-01 Bolt Biotherapeutics Inc Thianozapine immunoconjugates and uses thereof
TW202128765A (zh) * 2019-11-21 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種雙特異性抗體
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CA3186059A1 (en) 2020-08-13 2022-02-17 Romas Kudirka Pyrazoloazepine immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
WO2022125891A2 (en) 2020-12-11 2022-06-16 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
WO2022130348A1 (en) 2020-12-18 2022-06-23 Lamkap Bio Beta Ag Bispecific antibodies against ceacam5 and cd47
TW202304520A (zh) 2021-03-26 2023-02-01 美商博特生物治療公司 ２－胺基－４－羧醯胺－苯并氮呯免疫結合物及其用途
KR20230163450A (ko) 2021-03-26 2023-11-30 볼트 바이오테라퓨틱스 인코퍼레이티드 2-아미노-4-카복사마이드-벤즈아제핀 면역접합체 및 이의 용도
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
WO2023180489A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
DE69130113T2 (de) 1990-12-05 1999-05-12 Novo Nordisk A/S, Bagsvaerd Proteine mit geänderten epitopen und verfahren zur deren herstellung
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
WO1997000957A1 (en) 1995-06-23 1997-01-09 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
EP1348715A3 (en) 1998-04-21 2003-11-19 Micromet AG CD19xCD3 specific polypeptides and uses thereof
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
EP1361891A2 (en) 2001-02-19 2003-11-19 MERCK PATENT GmbH Artificial fusion proteins with reduced immunogenicity
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
WO2005040220A1 (en) 2003-10-16 2005-05-06 Micromet Ag Multispecific deimmunized cd3-binders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US20090226444A1 (en) * 2005-12-21 2009-09-10 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
ZA200805400B (en) * 2005-12-21 2009-09-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA

Also Published As

Publication number Publication date
KR20080079330A (ko) 2008-08-29
EP1976880B1 (en) 2016-07-06
IL192277A0 (en) 2008-12-29
PL1976880T3 (pl) 2017-01-31
ZA200805400B (en) 2009-09-30
AU2006328886C1 (en) 2011-11-17
CN101370827A (zh) 2009-02-18
JP2013056885A (ja) 2013-03-28
RU2008129787A (ru) 2010-01-27
DK1976880T3 (en) 2016-09-26
KR101287777B1 (ko) 2013-07-23
US20130273050A1 (en) 2013-10-17
CN101370827B (zh) 2015-10-14
HUE031151T2 (en) 2017-06-28
AU2006328886A1 (en) 2007-06-28
HK1115890A1 (zh) 2008-12-12
LT1976880T (lt) 2016-10-10
HRP20161216T1 (hr) 2016-11-18
RU2573893C2 (ru) 2016-01-27
WO2007071426A1 (en) 2007-06-28
US20090226432A1 (en) 2009-09-10
JP2009520734A (ja) 2009-05-28
PT1976880T (pt) 2016-09-28
US20170137538A1 (en) 2017-05-18
EP2527370A1 (en) 2012-11-28
JP5399712B2 (ja) 2014-01-29
US9695250B2 (en) 2017-07-04
NZ569204A (en) 2012-03-30
CA2633766A1 (en) 2007-06-28
CA2633766C (en) 2016-06-28
ME02581B (me) 2017-06-20
US9982063B2 (en) 2018-05-29
RU2426743C2 (ru) 2011-08-20
RS55181B1 (sr) 2017-01-31
SG193141A1 (en) 2013-09-30
ES2595091T3 (es) 2016-12-27
EP1976880A1 (en) 2008-10-08
BRPI0620632A2 (pt) 2011-12-20
IL192277A (en) 2016-08-31
AU2006328886B2 (en) 2011-04-14
RU2010148652A (ru) 2012-06-10
US8394926B2 (en) 2013-03-12

Similar Documents

Publication Publication Date Title
CY1118053T1 (el) Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea
CY1122270T1 (el) Αντι-παραγοντα xi μονοκλωνικα αντισωματα και μεθοδοι χρησης αυτων
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
CY1118369T1 (el) Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος
CY1116376T1 (el) Τρισθενη, διειδικα αντισωματα
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
CY1118713T1 (el) Βιολογικα προϊοντα
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
CY1117922T1 (el) Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
MX2020011554A (es) Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19).
RS53168B (en) Antibodies and Immunoconjugates and Their Use
UY31466A1 (es) Anticuerpos monoclonales que se unen al hgm-csf y las composiciones médicas que los comprenden
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
EA200600275A1 (ru) Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения
PE20110797A1 (es) Anticuerpos anti mn
UA114879C2 (uk) Антитіло до cd38 для лікування раку
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3